Huntingdon Life Sciences and Harlan Laboratories Appoints Corporate Vice President
News May 30, 2015
Huntingdon Life Sciences and Harlan Laboratories have announced the appointment of Joseph Bedford, Ph.D. as Corporate Vice President of Global Strategic Marketing. The creation of this new position strengthens the two firms’ international strategic marketing function across its Contract Research Services (CRS) and Research Models Services (RMS) business units.
Dr. Bedford’s responsibilities include global marketing, business intelligence, strategic planning and aspects of corporate development. He heads up a global team of 19 staff and is a member of the firm’s Executive Leadership Team.
Prior to joining Huntingdon and Harlan, Dr. Bedford served as Vice President of Global Marketing at Taconic Biosciences, where he implemented a corporate renaming and rebranding initiative, enhanced CRO sales channel strategies and acted as the global lead of the marketing function for research models and services.
Dr. Bedford’s other experience includes stints with Covance and the Almac Group covering a twelve year period. While serving as Associate Director of Global Market Research and then Director of Marketing and Strategy at Covance, Dr. Bedford played a key role in supporting decision making on business strategy, market positioning, and corporate development over a period in which Covance doubled its revenues from $800m to $1.7b.
As Director of Marketing at the Almac Group, he was responsible for re-positioning the clinical technologies services business unit, helping it grow 4x, and leading the marketing efforts of Almac’s integrated clinical service offerings.
Commenting on Dr. Bedford’s appointment, Dr. Adrian Hardy, Chief Operating Officer at Huntingdon Life Sciences and Harlan Laboratories commented: “We are delighted that Joe has joined the organization. This is an especially important time for us as we continue to develop the combined, integrated brand of the two companies. Joe’s strong expertise in strategic marketing across both the CRS and RMS CRO space will prove to be a great asset to the organization, and he brings an experienced new voice to the team.”
Remarking on his appointment, Dr. Bedford said: “I am very pleased to take on this position and look forward to playing my part in rebranding these two market leading companies and their subsidiaries to create a dynamic new firm that is well positioned for future growth. This is an ideal time to join the organization given the enormous potential of the combined entity in the marketplace. We are already seeing the benefits of bringing these businesses together - it is exciting our customers, our employees and all the stakeholders in our new company.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE